Literature DB >> 23167578

Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.

Geoffrey K Isbister1, Colin B Page.   

Abstract

There has been an increasing focus on drug induced QT prolongation including research on drug development and QT prolongation, following the removal of drugs due to torsades de pointes (TdP). Although this has improved our understanding of drug-induced QT prolongation there has been much less research aimed at helping clinicians assess risk in individual patients with drug induced QT prolongation. This review will focus on assessment of drug-induced QT prolongation in clinical practice using a simple risk assessment approach. Accurate measurement of the QT interval is best done manually, and not using the measurement of standard ECG machines. Correction for heart rate (HR) using correction formulae such as Bazett's is often inaccurate. These formulae underestimate and overestimate the duration of cardiac repolarization at low and high heart rates, respectively. Numerous cut-offs have been suggested as an indicator of an abnormal QT, but are problematic in clinical practice. An alternative approach is the QT nomogram which is a plot of QT vs. HR. The nomogram has an 'at risk' line and QT-HR pairs above this line have been shown in a systematic study to be associated with TdP and the line is more sensitive and specific than Bazett's QTc of 440 ms or 500 ms. Plotting the QT-HR pair for patients on drugs suspected or known to cause QT prolongation allows assessment of the QT interval based on normal population QT variability. This risk assessment then allows the safer commencement of drugs therapeutically or management of drug induced effects in overdose.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23167578      PMCID: PMC3703227          DOI: 10.1111/bcp.12040

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  65 in total

1.  Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.

Authors:  Y G Yap; J Camm
Journal:  BMJ       Date:  2000-04-29

Review 2.  How to correct the QT interval for the effects of heart rate in clinical studies.

Authors:  Patrick Davey
Journal:  J Pharmacol Toxicol Methods       Date:  2002 Jul-Aug       Impact factor: 1.950

Review 3.  The cardiotoxicity of macrolides: a systematic review.

Authors:  Daihong Guo; Yun Cai; Dong Chai; Beibei Liang; Nan Bai; Rui Wang
Journal:  Pharmazie       Date:  2010-09       Impact factor: 1.267

4.  Digital Holter measurement of QT prolongation in ziprasidone overdose.

Authors:  Ingrid Berling; Geoffrey K Isbister; Leonie Calver; Sally Clunas
Journal:  Clin Toxicol (Phila)       Date:  2011-08-08       Impact factor: 4.467

5.  Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval.

Authors:  M Malik; P Färbom; V Batchvarov; K Hnatkova; A J Camm
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

6.  QT interval prolongation associated with quetiapine (Seroquel) overdose.

Authors:  P Gajwani; L Pozuelo; G E Tesar
Journal:  Psychosomatics       Date:  2000 Jan-Feb       Impact factor: 2.386

7.  Bupropion overdose: QTc prolongation and its clinical significance.

Authors:  Geoffrey K Isbister; Corrine R Balit
Journal:  Ann Pharmacother       Date:  2003 Jul-Aug       Impact factor: 3.154

8.  Cardiac abnormalities in acute organophosphate poisoning.

Authors:  S Anand; Surjit Singh; Uma Nahar Saikia; Ashish Bhalla; Yash Paul Sharma; Dalbir Singh
Journal:  Clin Toxicol (Phila)       Date:  2009-03       Impact factor: 4.467

9.  Diuretic-induced hypokalaemia inducing torsades de pointes.

Authors:  J P Chvilicek; B J Hurlbert; G E Hill
Journal:  Can J Anaesth       Date:  1995-12       Impact factor: 5.063

10.  Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.

Authors:  Søren Fanoe; Christian Hvidt; Peter Ege; Gorm Boje Jensen
Journal:  Heart       Date:  2007-03-07       Impact factor: 5.994

View more
  40 in total

1.  Prolongation of the QTc interval in HIV-infected individuals compared to the general population.

Authors:  Nico Reinsch; Marina Arendt; Marie Henrike Geisel; Christina Schulze; Volker Holzendorf; Anna Warnke; Till Neumann; Norbert H Brockmeyer; Dirk Schadendorf; Lewin Eisele; Raimund Erbel; Susanne Moebus; Karl-Heinz Jöckel; Stefan Esser
Journal:  Infection       Date:  2017-08-03       Impact factor: 3.553

2.  Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation.

Authors:  Ana Carolina Moreira Souza; Andrea Grabe-Guimarães; Jader Dos Santos Cruz; Artur Santos-Miranda; Charlotte Farah; Liliam Teixeira Oliveira; Alexandre Lucas; Franck Aimond; Pierre Sicard; Vanessa Carla Furtado Mosqueira; Sylvain Richard
Journal:  Br J Pharmacol       Date:  2020-08-24       Impact factor: 8.739

3.  Therapeutics in clinical toxicology: in the absence of strong evidence how do we choose between antidotes, supportive care and masterful inactivity.

Authors:  Geoffrey K Isbister; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2016-03       Impact factor: 4.335

4.  Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies.

Authors:  Igor Diemberger; Emanuel Raschi; Gianluca Trifirò
Journal:  Clin Drug Investig       Date:  2017-10       Impact factor: 2.859

5.  Clinically significant incidental QTc prolongation is subject to within-individual variability.

Authors:  Itai Gueta; Robert Klempfner; Noa Markovits; Hillel Halkin; Shlomo Segev; David Rott; Yael Peled; Ronen Loebstein
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-09-09       Impact factor: 1.468

6.  Clemizole hydrochloride blocks cardiac potassium currents stably expressed in HEK 293 cells.

Authors:  Ling-Jun Jie; Wei-Yin Wu; Gang Li; Guo-Sheng Xiao; Shetuan Zhang; Gui-Rong Li; Yan Wang
Journal:  Br J Pharmacol       Date:  2017-01-12       Impact factor: 8.739

7.  Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.

Authors:  Perrine Courlet; Monia Guidi; Anaïs Glatard; Susana Alves Saldanha; Matthias Cavassini; Thierry Buclin; Catia Marzolini; Chin B Eap; Laurent A Decosterd; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2019-07-07       Impact factor: 4.335

8.  Implementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patients.

Authors:  Simone Schächtele; Thomas Tümena; Karl-Günter Gaßmann; Martin F Fromm; Renke Maas
Journal:  Dtsch Arztebl Int       Date:  2014-04-11       Impact factor: 5.594

Review 9.  Risk assessment of drug-induced QT prolongation.

Authors:  Geoffrey K Isbister
Journal:  Aust Prescr       Date:  2015-02-02

10.  Propofol-associated QTc prolongation.

Authors:  Michael J Scalese; Holly R Herring; R Chris Rathbun; Grant H Skrepnek; Toni L Ripley
Journal:  Ther Adv Drug Saf       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.